FDA creates new pathway to encourage domestic animal drug production
The Center for Veterinary Medicine program provides regulatory incentives for companies investing in U.S.-based manufacturing and testing capabilities.
The U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) has launched a new pilot program designed to encourage domestic manufacturing of animal drug products and their active pharmaceutical ingredients (APIs), an effort aimed at strengthening the veterinary pharmaceutical supply chain and reducing the risk of future drug shortages.
Under the initiative, the FDA will prioritize the review of certain animal drug submissions when both the finished drug product and its active ingredients are manufactured in the United States. Agency officials said the program supports broader federal efforts to expand U.S.-based pharmaceutical manufacturing while improving the resilience of the animal health supply chain.
“The veterinary pharmaceutical supply chain, like its human drug counterpart, relies significantly on active ingredients and finished products manufactured outside the United States,” the FDA said in a release. “The new pilot program is intended to reduce the risk of supply chain disruptions by prioritizing reviews of animal drug applications where both finished drug products and the active ingredients are manufactured in the U.S.”
According to the FDA, sponsors participating in the pilot program may receive expedited review of manufacturing and quality-related portions of eligible submissions, provided both the finished dosage form and the drug substance are manufactured domestically. The agency said the program is intended to create a regulatory incentive for companies considering expanding or relocating manufacturing operations to the United States.
The pilot applies to several submission types, including new animal drug applications and abbreviated new animal drug applications, as well as certain supplemental applications. Eligible companies must identify their interest in participating when submitting their application and meet specific program requirements outlined by the FDA.
The FDA emphasized that the initiative does not alter its standards for safety, effectiveness or product quality. Instead, the program provides review prioritization as an incentive while maintaining the agency’s existing scientific and regulatory requirements.
Encouraging U.S.-based manufacturing and testing capabilities
For veterinarians and animal health manufacturers, the initiative could help improve long-term availability of important medications by encouraging greater domestic production capacity. Industry groups have increasingly raised concerns in recent years about supply disruptions affecting antibiotics, anesthetics and other commonly used veterinary products, highlighting the need for a more resilient manufacturing network.
The pilot is modeled after similar FDA initiatives for human drugs, including the Abbreviated New Drug Application (ANDA) Prioritization Pilot and the PreCheck Pilot Program, but has been tailored specifically to the veterinary pharmaceutical regulatory framework. The agency said the program is intended to encourage companies to invest in U.S.-based manufacturing and testing capabilities while maintaining existing statutory and regulatory standards for product approval.
To qualify, sponsors must manufacture both the finished animal drug product and its active pharmaceutical ingredient in the United States. The FDA noted that review prioritization may apply to original new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and certain supplemental applications. Participation is voluntary, and eligible sponsors must notify the Center for Veterinary Medicine of their intent to participate when submitting their application. The agency said the program will be evaluated over time to determine its effectiveness in strengthening the domestic veterinary drug supply chain and reducing the risk of future shortages
The FDA said additional information, including eligibility criteria and application procedures, is available through the CVM Pilot Program to Support Animal Drug Manufacturing and Testing in the United States.
- Boosting domestic production:
The FDA program is designed to encourage manufacturers to produce animal drug products and active pharmaceutical ingredients in the United States.
- Priority review incentive:
Eligible animal drug applications that meet the program requirements may receive expedited review of certain manufacturing and quality-related sections.
- Strengthening supply chain resilience:
The initiative aims to reduce vulnerabilities caused by global supply chain disruptions and improve the availability of critical veterinary medications.
Photo Credit:
istockphoto.com/DenGuy
